With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.137076-54-1,2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid,as a common compound, the synthetic route is as follows.
Example 6.1 Preparation of compounds 30a-b- General Procedure: HBTU (1 eq) and DIPEA (1.7 eq) were sequentially added to a suspension ofcompound 26 in CH2CI2 (concentration 1% w/v) and the mixture was keptunder stirring at room temperature for 30 min; phosphoethanolamine (DLPEn = 10 or DMPE n = 12) (1 eq) was then added and the mixture was maintained under stirring at room temperature for 24 h. The reactionmixture was sequentially washed with H20 (100 mL), acidified H20 (pH 4-5with HCI; 100 mL) and H20 (100 mL). The organic layer was dried(Na2S04), filtered and evaporated, and the so-obtained crude material waspurified by flash chromatography to obtain compounds 30a-b. Example 6.1a Preparation of 10-[(10R)-7-hydroxy-7-oxido-2,13-dioxo-10-[(1-oxododecyl)oxy]-6,8,12-trioxa-3-aza-7-phosphatetracos-1-yl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid tris [(1,1-dimethyl)ethyl] ester 30aReagents: Compound 26 (968 mg; 1.69 mmol); 1,2-didodecanoyl-sn-glycero-3-phosphoethanolamine (980 mg; 1.69 mmol).Compound 30a (605 mg, 0.53 mmol); Yield 32%.Analytical dataHPLC-ELSD: 40.6% (area%)Mr: 1134.48 (C57H 108N5015P) 1H-and 13C-NMR and MS are compatible with the structure.
137076-54-1, 137076-54-1 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid 11606627, acatalyst-ligand compound, is more and more widely used in various fields.
Reference£º
Patent; BRACCO IMAGING SPA; GHIANI, Simona; MAIOCCHI, Alessandro; BRIOSCHI, Chiara; VISIGALLI, Massimo; CABELLA, Claudia; MIRAGOLI, Luigi; WO2014/37498; (2014); A2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI